An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

NCT05210530 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Disease
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases

Interventions

COMBINATION_PRODUCT: VCTX210A unit

Sponsor

CRISPR Therapeutics AG

Collaborators

[object Object]